(Q46813506)

English

Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

5

object named as

Yoshinori Ito

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

6

object named as

Shinji Ohno

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

4

object named as

Hiroji Iwata

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

2

object named as

Masakazu Toi

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

1

object named as

Shigehira Saji

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

author name string

Satoshi Morita

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

Tadashi Kobayashi

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

Yasuo Hozumi

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

Junichi Sakamoto

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

72

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

5-6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

330-337

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Capecitabine: preclinical pharmacology studies

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Clinical pharmacokinetics of capecitabine

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1159%2F000113062

21 January 2018

Identifiers

10.1159/000113062

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18187954

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46813506&oldid=2144562977"